PCS PHARMACY MANAGED CARE PROGRAM SETS PAYMENT AT AWP MINUS 10%
• By The Pink Sheet
PCS PHARMACY MANAGED CARE PROGRAM SETS PAYMENT AT AWP MINUS 10% or the pharmacy's usual and customary retail price -- whichever is lower. PCS explained its payment structure in a proposed contract and managed care program information sent to the 52,000 pharmacies currently participating in the PCS RECAP electronic claims submission and adjudication network. PCS is gearing up to offer the managed care program to its health insurance plan clients on Jan. 1, 1993. A program summary prepared for pharmacies explains: "In most cases, a client's participation in a Managed Care Program with PCS will prevent a switch to other competitors' programs [that have] lower reimbursement, restricted pharmacy networks and a bias to mailorder alternatives." The pharmacist "plays an important role in ensuring the success of many managed care programs," the PCS summary states. "However, to succeed in establishing a reimbursement that is both fair and equitable to all, the parties must recognize standards that have been established in today's marketplace by a competitive focus on ingredient cost, without regard to delivery of quality of care. Because so many payers are now aware of the discounts on drug purchases which are widely available," PCS added, "they have changed the reimbursement from full average wholesale price to 90% AWP, and often less." The summary advises that "more than 40% of PCS's clients use this type of reimbursement; in the near future, we expect as many as 80% of our membership base to demand coverage through a 90% AWP network." The Scottsdale, Ariz.-based subsidiary of McKesson handles prescription drug benefits for 20 mil. individuals. It has just announced its largest contract, managing drug claims for more than 3 mil. federal government employees and retirees who choose Blue Cross and Blue Shield plans for their health insurance ("The Pink Sheet" July 20, T&G-2). The federal contract, also slated to be up and running Jan. 1, includes a preferred provider network of 21,000 pharmacies. PCS is trying to position the Managed Care Program as an "acceptable alternative" to other programs that generate savings primarily through cutting pharmacy retail payments. When fully implemented, the managed care project will include other "program enhancements" designed to promote "cost effective, quality programs," including "enhanced" drug utilization review, strengthened generic substitution and a formulary program. For maintenance drugs, the plan sponsor may choose to direct patients to a "community pharmacist who is able to compete with mail-order programs because of extended days supply and incremental dispensing fees," PCS said. Specific elements of the Managed Care Program can be tailored to individual clients. For some of its clients, PCS currently bases its formularies in part on provision of manufacturer rebates. The PCS summary for pharmacists stresses that participation in "formulary programs [does] not reduce pharmacy reimbursement." PCS is also considering "potentially higher reimbursement for pharmacists who demonstrate superior capability in managing care by providing interventions that improve quality in a cost- effective manner." While details of this proposal are yet to be worked out, a PCS spokesperson said that, for example, a pharmacy might receive financial rewards if it helped hold down a plan's health care costs by monitoring compliance with drug regimens. In some cases, pharmacies may have to upgrade their computer capabilities to participate in the Managed Care Program.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.
Sam Roberts, chief executive of England’s NICE, has defended the health technology assessment institute’s cost-effectiveness thresholds and the country’s ranking against other nations when it comes to market access, while acknowledging that the UK’s pharma ecosystem is “really tough.”
The 27-year agency veteran has not been formally approached about filling the vacancy created by George Tidmarsh’s resignation, but also is not interested in the position, the Pink Sheet has learned.